According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

U.S. health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

Shares in Valneva slumped around 25% on Monday after the French drugmaker said the United States Food and Drug Administration ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

There have been 4 new reports of serious adverse events related to Ixchiq based on updated Vaccine Adverse Event Reporting System data.

US health authorities suspended the license for the Ixchiq vaccine on Monday after new cases of adverse reactions, mainly ...

The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with ...

The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq ...